1 Department of Nephrology, Clinical Center Skopje, University of Skopje, Macedonia and 2 Department of Nephrology-Hypertension, University of Antwerp, Belgium
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Methods. Transiliac bone biopsies were taken in an unselected group of 84 ESRF patients (44 male, age 54±12 years) before enrolment in a dialysis programme. All patients were recruited within a time period of 10 months from various centres (n=18) in Macedonia. Calcium carbonate was the only prescribed medication in patients followed up by the outpatient clinic.
Results. HPTH was found in only 9% of the patients, whilst ABD appeared to be the most frequent renal bone disease as it was observed in 23% of the cases next to normal bone (38%). A relatively high number of patients (n=10; 12%) fulfilled the criteria of osteomalacia (OM). Mixed osteodystrophy (MX) was diagnosed in 18% of the subjects. There was no significant difference between groups in age, creatinine, or serum and bone strontium and aluminium levels. Patient characteristics associated with ABD included male gender and diabetes, whilst OM was associated with older age (>58 years).
Conclusions. In an unselected population of ESRF patients already, 62% of them have an abnormal bone histology. ABD is the most prevalent type of ROD in this population. In the absence of aluminium or strontium accumulation the relatively high prevalence of a low bone turnover as expressed by either normal bone or ABD and OM is striking.
Keywords: adynamic bone disease; ESRF; hyperparathyroidism; osteomalacia; predialysis; renal osteodystrophy
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The earliest reports have shown hyperparathyroid bone disease (HPTH) [6] to be the predominant form of ROD. Osteomalacia (OM) developed as a consequence of aluminium-intoxication [7], vitamin D deficiency and the presence of metabolic acidosis in CRF patients not yet on dialysis [8]. Recently, OM has also been associated with strontium accumulation [9]. In recent years, adynamic bone disease (ABD) has become the most prevalent bone lesion within the dialysis population. This type of ROD was first found in association with high bone aluminium (B-Al) levels [10]. Recent reports, however, have shown that the prevalence of ABD has increased up to 60 and 36% for continuous ambulatory peritoneal dialysis (CAPD) and haemodialysis (HD) patients, respectively, regardless of the absence of a distinct bone surface aluminium [3,5,11].
Studies on ROD in pre-dialysis patients are scarce. In the earliest reports the prevalence of ROD in pre-dialysis patients has varied between 40 and 100% [1215] with predominant HPTH [4,16]. Two Spanish studies reported an increased prevalence of ABD in end-stage renal failure (ESRF) patients not yet in dialysis of 32 and 48%, respectively [17,18]. A recent study in 76 pre-dialysis patients showed a somewhat different pattern. Here the mild mixed (HPTH+OM) type of ROD (MX) was most prevalent in 36%, advanced MX was diagnosed in 29%, and ABD and OM in 12 and 9% of the patients, respectively [19]. It should be noted that in the latter study the degree of renal insufficiency widely differed from patient-to-patient. In a recent Asian study in 56 pre-dialysis patients, 91% of the cases presented with ROD [20]. Mild and severe osteitis fibrosa (OF) was found in 36 and 9% and ABD and OM in 24 and 10% of the patients, respectively. A similar distribution pattern was found in the study of Ballanti et al. [21] in 27 pre-dialysis patients with various degrees of renal failure. Here, the prevalence of ABD was 22% whilst OM was diagnosed in 11%, HPTH in 8% and MX in 59% of the patients.
The differences in the spectrum of ROD reported by the various study groups can, at least in part, be explained by differences in criteria for patient recruitment (selected vs unselected populations), cohort size, genetic and dietary factors, referral rates and use of phosphate binding agents.
In the present study, data on the spectrum of ROD are presented from a pre-dialysis population treated with a single phosphate binder.
The purpose of the study was to: (i) describe the distribution of the different types of ROD in an unselected population of patients not yet on dialysis recruited from a single geographic area within a time period of only 10 months, (ii) establish risk factors that might influence the development of the various types of ROD.
![]() |
Subjects and methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Calcium carbonate (3 g/day) was the only phosphate binder used and was taken by 59 patients (70%). None of the patients received either vitamin D analogues or erythropoietin before commencing dialysis. All patients had a creatinine clearance of <5 ml/min. The causes of renal failure were chronic glomerulonephritis in 13 patients (15%), interstitial kidney disease in 16 (19%), nephrosclerosis in 23 (27%) and a group of 14 patients (17%) with undefined diagnosis. Ten patients (12%) were affected by insulin-dependent diabetes mellitus. There were three patients with polycystic kidney disease, amyloidosis was noticed in two patients and multicystic disease, obstructive nephropathy and uric nephropathy were diagnosed in one case each.
The protocol was approved by the Ethical Committee of the Medical Faculty, University of Skopje, Macedonia.
Bone biopsy
Transiliac bone biopsies were obtained using a Bordier-Meunier needle with an internal diameter of 5 mm, after double tetracycline labelling with a 14-day interval according to a standardized protocol [6]. The biopsies were performed 37 days after the second labelling session. Each specimen was transversally divided in two pieces. The largest part was used for histological examination and the second part was weighed directly after sampling and used for bulk analysis by means of electrothermal atomic absorption [22,23]. Histomorphometric analysis was performed on 5 µm Goldner stained undecalcified, methylmetacrylate embedded bone sections. For the detection and localization of aluminium the sections were stained with Aluminon®. Unstained sections (7 µm) were used for the evaluation of tetracycline labels by fluorescence microscopy.
Histological sections were analysed and quantified using a Leica DMRB microscope equipped with a colour CCD camera and a KS 400 image analysis system. Calibration of image pixel size was performed before each measurement cycle using a calibration grid. Bone area, osteoid area, osteoid perimeter, eroded perimeter and quiescent perimeter were measured by manually tracing the mineralized and osteoid area and marking erosion lacunae on the computer screen after which the system calculated the areas and perimeters. Double labelled perimeter and total perimeter were measured in a similar way on unstained sections. Inter-label distance was measured by tracing the labels, after which the system measured the distances between the labels at regular intervals, perpendicular to the labels. Per section, 1015 consecutive fields were analysed. Out of these primary measurements, the following derived parameters were calculated according to standardized procedures [24]. Bone area [BAR (%)]: the area of trabecular bone including both mineralized bone and osteoid, expressed as a percentage of the total tissue area. Osteoid area [OAR (%)]: the measured area of osteoid expressed as a percent of total BAR. Osteoid width [OWI (µm)]: the mean width of surface osteoid seams, calculated by dividing the measured osteoid area by the length of the osteoid seams. Osteoid perimeter [OPM (%)]: trabecular bone perimeter occupied by osteoid as a percentage of the total bone perimeter. Eroded perimeter [EPM (%)]: the percentage of trabecular bone perimeter characterized by the presence of scalloped bone resorptive lacunae. Double labelled perimeter [DLPM (%)]: percentage of total endosteal perimeter exhibiting a double fluorescent tetracycline label. Mineral apposition rate [MAR (µm/day)]: the rate by which osteoid is mineralized, calculated as the average distance between midpoints of two consecutive tetracycline labels, divided by the time interval between the labelling periods. Adjusted apposition rate [AJAR (µm/day)]: mineral apposition rate averaged over the entire osteoid perimeter. The latter concept is important because in a steady state and in the absence of OM the adjusted apposition rate is the best estimate available from a biopsy of the mean rate of osteoid apposition. Mineralization lag time [MLT (days)]: mean interval between deposition and mineralization of any infinitesimal volume of matrix, averaged over the entire life span of the osteoid seam. Bone formation rate [BFR (µm2/mm2/day)]: area of bone formed per unit of time, calculated as the product of mineral apposition rate and mineralizing perimeter; the latter is calculated as the sum of doubly labelled plus half of singly labelled perimeter per bone perimeter. Bone histological data as well as dynamic parameters are reported using standardized nomenclature and definitions that have repeatedly been used in previous studies of our and other groups [5,6,2426]. Quantitative measurements are expressed in two dimensions. Thus, osteoid area [two-dimensional (2D)] corresponds to osteoid volume [three-dimensional (3D)], osteoid perimeter to osteoid surface and osteoid width to osteoid thickness. For conversion of 2D to 3D we refer to Parfitt [25].
Based on the values obtained in normal controls, classification of the various types of ROD was carried out according to the following criteria. Normal histology: osteoid area <12%, no fibrosis, BFR 97613 µm2/mm2/day. Mild hyperparathyroidism (HPTH): osteoid area <12%, no fibrosis, BFR >613 µm2/mm2/day. OF: osteoid area <12%,with fibrosis, BFR> 613 µm2/mm2/day. OM: osteoid area >12%, no fibrosis, BFR <97 µm2/mm2/day. ABD: osteoid area <12%, no fibrosis, BFR <97 µm2/mm2/day. Mixed lesion: osteoid area >12%, with fibrosis. The biopsies were examined and classified by three different observers without knowledge of the biochemical and clinical findings. The bone aluminium (B-Al) and bone strontium (B-Sr) concentrations were determined by electrothermal atomic absorption spectrometry with Zeeman background correction (Perkin-Elmer Zeeman 3030; graphite furnace HGA 600) [22,23]. We also determined the calcium concentration in bone (B-Ca) to correct for differences in bone density. Calcium was determined with atomic absorption spectrometry with flame atomization (Perkin-Elmer Model 3110). B-Al and B-Sr levels of dialysis patients are considered not to be associated with aluminium or strontium-related bone disease when <14 µg/g wet weight and <60 µg/g wet weight, respectively [9,26].
Biochemical parameters
Blood samples for the determination of biochemical parameters were obtained prior to the start of the first dialysis session. After immediate centrifugation 3 ml serum samples were stored and shipped to the laboratory in dry test tubes at -80°C for the determination of a number of relevant biochemical parameters of bone turnover and aluminium and strontium. Intact parathormone (iPTH) and osteocalcin were measured with an immuno radiometric assay (IRMA) (Biosource S.A, Europe). The Bio-Rad Crosslinks kit was used in combination with an in-house developed method for the HPLC measurement of pyridinolines (PYD) and deoxypyridinolines (DPYD) in urine (Bio-Rad Laboratories GmbH, Munchen, Germany) [27]. Calcium (Se-Ca), phosphorus (Se-P) and total alkaline phosphatase (TAP) in serum were measured by standard automated techniques. Aluminium (Se-Al) and strontium (Se-Sr) in serum were measured with the same technique as that used for bone analysis [22,23]. The laboratory threshold values for these parameters in dialysis patients are <30 µg/l and <100 µg/l, respectively [26,28]. Bone alkaline phosphatase (BAP) was quantified following electrophoretic separation on an agarose gel (ISOPAL-kit) as described previously by Van Hoof et al. [29].
Histomorphometric and (bio)chemical analyses in bone and serum were performed at the Department of Nephrology of the University of Antwerp, Belgium.
Statistical analysis
Comparison between groups of the various parameters under study in serum and bone was performed by means of KruskalWallis, followed by the MannWhitney rank sum test for further comparison between two separate groups. A comparison of the percentage of patients belonging to categorical variables: sex, diabetes, late vs early referrals and calcium carbonate intake in the various ROD groups was performed by 2 analysis, followed by Fisher's exact test for comparison between two separate groups. A P value <0.05 was considered to be significant at a two-tailed level. Results are expressed as median (range) for serum biochemistry and bone histomorphometry.
To establish the risk factors that might be associated with the development of a various types of ROD a stepwise logistic regression model was used. Non-significant covariates were eliminated by backward selection. Covariates (binominal or continuous) were considered predictive for a particular type of ROD when the estimated coefficient was significantly different from 0 based on the Wald statistic (P<0.05) and expressed in the form of odds ratios. Age, gender of the patients, diabetes, calcium carbonate intake, late/early referral ratio and duration of the follow-up by the nephrologist prior to entering dialysis were included in all models. Statistical analysis was performed using the SPSS 10.0 for Windows statistical software.
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
|
|
|
In the assessment of risk factors for the various types of ROD logistic regression analysis identified three significant independent covariates in the development of ABD; i.e. patients' gender, diabetes and late referral (Table 4). Although the male/female ratio did not differ significantly from the other ROD groups as assessed by Fisher's exact test, risk analysis revealed male patients to be at a higher risk for the development of ABD (P<0.05). Patients with diabetic nephropathy also turned out to be at a higher risk for ABD (P=0.052), which is also reflected by the significantly higher prevalence of insulin dependent diabetes mellitus in the ABD group compared with the other forms of ROD (P<0.01). Patients who were referred to the nephrologist within the last 6 months prior to hospitalization were more likely to have ABD at the borderline of significance (P=0.076).
|
Although the male/female gender ratio was significantly higher in patients with HPTH in comparison with the other ROD groups, logistic regression analysis revealed that male gender did not significantly (P=0.075) predispose to an increased risk for the development of HPTH, which perhaps, can be ascribed to the limited number of patients presenting this type of ROD.
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The majority of patients (38%) presented with a normal bone histology, a finding that considerably differs from the ROD spectra reported previously in non-dialysed renal failure patients [4,17,18,20]. In two recent Spanish [17,18] studies and that of Hutchison et al. [4] none of the patients was reported to have normal bone histology, whilst in a very recent Asian study 8.6% of the patients were diagnosed with this histological picture [20]. Hamdy et al. found 25% (44 out of 176) of their pre-dialysis patients to present a normal bone histology [1]. Here it should be noted that patients of the latter study still had a relatively high creatinine clearance (mean 35.9 ml/min) [1]. The rather conflicting literature data may to a certain extent be explained by the non-conformity in the histological standards used for classification of the various types of ROD (some authors do not include normal bone for differential diagnosis) and the selective nature of patient recruitment by the various research groups.
In the absence of any exposure to aluminium, ABD was found to be the second most prevalent (23%) histological picture next to normal bone. The observed prevalence of ABD is highly comparable with that noted in two other recent studies [20,21]. Interestingly, in agreement with our data, in the study of Shin et al. [20], ABD could also be associated with a relatively high number of late referrals (65.5%). A high prevalence (48 and 32%, respectively) of ABD was also reported by Torres et al. [17,23] and Hernandez et al. [18,24] in two Spanish pre-dialysis populations. To which extent subtle aluminium exposure might have contributed to the development of ABD in the latter populations is not clear.
In agreement with two previous reports [18,20], we found a relatively high prevalence of OM (12%, 10 out of 84 patients). This relatively high number of patients with OM was noticed in the absence of any increased exposure to either aluminium or strontium as reflected by the patients' low serum and bone levels of these elements. As Macedonia is a rather sunny country vitamin D deficiency is not readily expected. However, determination of both 25-OH vit D3 and 1,25-(OH)2 vit D3 in a separate group of 22 ESRF patients not yet in dialysis which were treated under the same clinical conditions and lived in the same region, showed both compounds to be in the low-normal range (25-OH vit D3: normal range 22130 ng/ml; median value study population, 37.5 ng/ml, five out of 22 patients <22 ng/ml and 1
,25-(OH)2 vit D3, normal range, 36144 pg/ml; median value study population, 53 pg/ml, seven out of 22 patients <36 pg/ml) pointing to a relative vitamin D deficiency in at least a subset of patients. In this context it is worth mentioning that in a recent study carried out in Algeria, being a sunny country also, osteomalacic lesions, diagnosed by the presence of Looser's zones, have been associated with decreased levels of 25-(OH) vit D3, [not 1
,25-(OH)2 vit D3] [30]. In support of this statement are the decreased serum calcium levels in the osteomalacic patients of the present study. The older age of the OM patients, probably with less sun exposure and hence lower vitamin D uptake to a certain extent fits with the proposed hypothesis also. To which extent other factors, e.g. acidosis might also have played a role in the development of OM is not clear. As reported previously by others [31], could the diet and nutritional status also contribute to the incidence of OM? In the present study the diet of all patients was quite similar and mainly consisted of dairy products and vegetables. Furthermore, the total protein levels in serum, that to a certain extent reflects the nutritional status, did not differ significantly between groups. In view of this, the role of this factor in the development of OM population seems to be limited in the present study population.
The relatively low prevalence of HPTH (9%) is striking and in general is lower than that reported in previous studies in pre-dialysis patients [4]. Differences in dietary habits, sun exposure or genetic predisposition, treatment with calcium carbonate (70% of the patients), are potential explanatory factors.
Using logistic regression analysis a series of the clinical data were evaluated as possible risk factors for the development of a particular type of ROD. To the best of our knowledge, this is the first study in which such an approach was used in pre-dialysis patients. Male patients tended to be at a higher risk for development of HPTH (odds ratio 7.0). Literature data obtained in dialysis patients showed opposite results as they indicated females to be at a higher risk for the development of HPTH whilst male gender could be associated with a higher incidence of ABD. Oestrogen deficiency and cessation of ovarian function in older amenorrhoeic women leading to a higher susceptibility to increased bone turnover could be an attractive explanation for these findings. The higher, although not statistically significant, male/female ratio noticed in the ABD group of the present study, to a certain extent agrees with the above statement and previous literature data.
A tendency towards a longer follow-up by the nephrologist (i.e. period between the first time the diagnosis of CRF was made and bone biopsy) in the HPTH vs the ABD group (mean follow-up periods of 27 and 8 months, respectively) was noted. Moreover the increased prevalence of late referral patients in the ABD group (14/19) was identified as an independent risk factor for the development of this type of bone disease. This observation might contribute to a better insight in the natural course of pre-dialysis ROD and might point towards an evolution from ABD towards HPTH with increasing referral time.
Our finding of an association between diabetic nephropathy and ABD confirms and extends observations made in previous reports [18,20]. In the present study as much as 60% of the diabetic patients presented with ABD, a percentage being considerably higher than that reported in previous Asian and Spanish studies reporting values of 44.4 and 23%, respectively.
Older age (>58 years) was found to be a risk factor for the development of OM. Reduced phosphorus intake, less sunlight exposure and hence altered vitamin D activity/metabolism might to a certain extent explain this observation, which is further supported by the low serum calcium levels in patients with OM.
Our data demonstrate a relatively high prevalence of low bone turnover as expressed by normal bone, ABD and OM in the absence of an increased exposure to aluminium or strontium. The only medication in connection with ROD was the use of calcium carbonate for phosphate binding (70% of the patients). As the percentages of patients taking calcium carbonate did not differ between groups, the possible speculation as should the high number of patients with low bone turnover be due to a relative suppression of PTH secretion secondary to the use of calcium-containing phosphate binders can not be withheld. In the absence of these various factors promoting the development of low bone turnover (i.e. aluminium, strontium and calcium carbonate) our data may again contribute to a better insight into the natural course of ROD in CRF.
With respect to possible associations between various types of ROD and biochemical parameters the increased serum calcium concentrations in ABD patients and decreased levels in OM patients as compared to the other ROD groups are of particular interest. Measurement of the serum calcium level thus could be helpful for the biochemical differentiation between these two types of low turnover bone disease. The differences in serum calcium levels were also reflected by the bone calcium concentration that was significantly lower in patients of the OM group compared with those having ABD.
Patients with OM also showed significantly higher levels of ferritin. Although interferences of iron with bone cell function and physicochemical interactions of the element with bone mineralization have been reported [32], further studies and additional clinical data are required to demonstrate an etiological role for iron in the development of OM.
In conclusion, in an unselected group of pre-dialysis patients recruited within a period of 10 months, from a well-defined geographic area (Macedonia) and in the absence of aluminium or strontium overload, 62% of the cases already presented with an abnormal bone histology. ABD is the most prevalent type of ROD in this population. In the absence of aluminium or strontium accumulation the relatively high prevalence of OM (12%) is striking. Patient characteristics associated with ABD included male gender, late referral and diabetes, whilst OM was associated with high patient age (>58 years) and serum calcium levels <7.1 mg/dl. Additional work is needed to determine whether even in sunny countries like Macedonia a deficient vitamin D status could at least in part explain the relatively high prevalence of OM and low prevalence of HPTH.
![]() |
Acknowledgments |
---|
Conflict of interest statement. None declared.
![]() |
Notes |
---|
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|